PMC:7558914 / 1139-1352
Annnotations
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"40","span":{"begin":158,"end":166},"obj":"Species"},{"id":"52","span":{"begin":1,"end":20},"obj":"Chemical"},{"id":"53","span":{"begin":53,"end":71},"obj":"Chemical"},{"id":"54","span":{"begin":73,"end":85},"obj":"Chemical"},{"id":"55","span":{"begin":91,"end":110},"obj":"Chemical"},{"id":"68","span":{"begin":179,"end":188},"obj":"Disease"}],"attributes":[{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"Tax:9606"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"MESH:C558899"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"MESH:D006886"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"MESH:D017963"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"MESH:C558899"},{"id":"A68","pred":"tao:has_database_id","subj":"68","obj":"MESH:D011014"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" lopinavir/ritonavir (46.7%) and triple therapy with hydroxychloroquine, azithromycin, and lopinavir/ritonavir (40%) were the most recommended treatments for patients with severe pneumonia. There were five cortico"}
LitCovid-PD-HP
{"project":"LitCovid-PD-HP","denotations":[{"id":"T3","span":{"begin":179,"end":188},"obj":"Phenotype"}],"attributes":[{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":" lopinavir/ritonavir (46.7%) and triple therapy with hydroxychloroquine, azithromycin, and lopinavir/ritonavir (40%) were the most recommended treatments for patients with severe pneumonia. There were five cortico"}